Package 0003-0371-13

{"route": ["INTRAVENOUS"], "spl_id": "9057087d-7e59-4e5a-8e4a-96a532efb0ab", "openfda": {"nui": ["N0000182829", "N0000182830", "N0000182150", "N0000182151"], "unii": ["E3B2GI648A"], "rxcui": ["1112976", "1112980"], "spl_set_id": ["c16ac648-d5d2-9f7d-8637-e2328572754e"], "pharm_class_pe": ["T Lymphocyte Costimulation Activity Blockade [PE]"], "pharm_class_epc": ["Selective T Cell Costimulation Blocker [EPC]"], "pharm_class_moa": ["CD80-directed Antibody Interactions [MoA]", "CD86-directed Antibody Interactions [MoA]"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (0003-0371-13)  / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE", "package_ndc": "0003-0371-13", "marketing_start_date": "20110615"}], "brand_name": "NULOJIX", "product_id": "0003-0371_9057087d-7e59-4e5a-8e4a-96a532efb0ab", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION", "pharm_class": ["CD80-directed Antibody Interactions [MoA]", "CD86-directed Antibody Interactions [MoA]", "Selective T Cell Costimulation Blocker [EPC]", "T Lymphocyte Costimulation Activity Blockade [PE]"], "product_ndc": "0003-0371", "generic_name": "BELATACEPT", "labeler_name": "E.R. Squibb & Sons, L.L.C.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "NULOJIX", "active_ingredients": [{"name": "BELATACEPT", "strength": "250 mg/1"}], "application_number": "BLA125288", "marketing_category": "BLA", "marketing_start_date": "20110615", "listing_expiration_date": "20261231"}